Burmester, G. R., Coates, L. C., Cohen, S. B., Tanaka, Y., Vranic, I., Nagy, E., . . . Kinch, C. (2023). Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Adis, Springer Healthcare.
Chicago Style (17th ed.) CitationBurmester, Gerd R., et al. Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Adis, Springer Healthcare, 2023.
MLA引文Burmester, Gerd R., et al. Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Adis, Springer Healthcare, 2023.
警告:這些引文格式不一定是100%准確.